Cancer Immunotherapy with Artificial Intelligence for Hospitals: Market Shares, Strategies, and Forecasts, Worldwide, 2017 to 2023

$4200 - Single Copy or $8400 - Web Posting | Report # SH272024732 | 124 Pages | 50 Tables and Figures | 2017


Qty
Authorize.net
  • Key Topics
  • Cancer Immunotherapy
  • Hospital Artificial Intelligence
  • AI Technology
  • Acurate Diagnosis
  • Healthcare Artificial Intelligence
  • Supervised machine learning
  • AI hospital techniques
  • AI Segmentation
  • AI dimensionality reduction
  • AI anomaly detection
  • AI pattern recognition
  • AI Replaces Supervised Manual Techniques For Diagnosis And Care Delivery

YOU MUST HAVE THIS STUDY


LEXINGTON, Massachusetts (October 17, 2017) – WinterGreen Research announces that it has published a new study Artificial Intelligence for Hospital Cancer Immunotherapy: Market Shares, Strategy, and Forecasts, Worldwide, 2017 to 2023.  The 2017 study has 124 pages, 50 tables and figures.  Worldwide markets are poised to achieve continuing growth as the artificial intelligence software increases diagnostic excellence, saving lives and lowering care delivery costs. 

Hospital Artificial Intelligence for Immunotherapy drives sales of analytics systems.

Automated cancer immunotherapies from IBM Watson are implemented with artificial intelligence that looks at patient samples to detect the genetic characteristics of the cancer and isolate the immune particularities of the patient.  Systems are able to take a multi-disciplinary integrated approach to looking at imaging and scans.  The analysis of patient records, looking for effectiveness of particular treatments is more work than a human can do, the quantity of data is too high, so the artificial intelligence is being used to do that.  

Personalized medicine is driving this market opportunity.

Systems are making a significant difference in saving lives.  

Memorial Sloan Kettering physician-scientists are among leaders in the field developing groundbreaking immune therapies that are helping to treat several forms of advanced cancer that were previously untreatable.  These scientists have played a lead role in developing and testing the immunotherapy drugs known as checkpoint inhibitors that “release the brakes” on the immune system.  

Hospital care management can leverage artificial intelligence.  Artificial intelligence is useful for providing highly tailored insights about individual patients for the purpose of personalizing immunotherapy care delivery.   Artificial intelligence is useful for helping providers effectively address healthcare delivery because it details genetic specificity regarding individual patients.

The intersection of healthcare and artificial intelligence represents a market opportunity.  New strategies are being developed by companies to bring A.I. to healthcare.  The business challenges around those efforts are being addressed collectively in partnerships and in forums to bring the technology into the market.   Artificial intelligence has an impact on patients, doctors, hospitals, clinical facilities, and the healthcare industry overall. 

The ability of an intelligent system to learn from data without upfront human intervention brings significant change to the healthcare delivery system.  It relies on the use of unsupervised and semi-supervised machine learning techniques.  Segmentation, dimensionality reduction, anomaly detection and pattern recognition are replacing supervised manual techniques for diagnosis and care delivery.  

According to Susan Eustis, lead author of the team that wrote the study, “Immunotherapy at Memorial Sloan Kettering (MSK) has been making enormous progress in the treatment of cancer.  At Memorial Sloan Kettering, immunotherapy is one of the most promising ways to treat, cure, and ultimately prevent cancer.  Immunotherapy at MSK has evolved new immune-based treatments for cancer.   Researchers have been at the epicenter of new discoveries in the field, and their work is bringing exciting new treatment options to people with cancer.”

Artificial Intelligence for Hospital Cancer Immunotherapy Market Forecasts

Cancer immunotherapy hospital artificial intelligence market system shipments at $7.4 billion in 2023 are forecast to reach $49.4 billion dollars, worldwide by 2023.    These artificial intelligence systems represent a very specialized type of care delivery.  Steady growth is anticipated because the severely ill patients with advanced cancer disease can be treated successfully with immunotherapy.

WinterGreen Research is an independent research organization funded by the sale of market research studies all over the world and by the implementation of ROI models that are used to calculate the total cost of ownership of equipment, services, and software.  The company has 35 distributors worldwide, including Global Information Info Shop, Market Research.com, Research and Markets, electronics.ca, Bloomberg, and Thompson Financial.  

WinterGreen Research is positioned to help customers facing challenges that define the modern enterprises. The increasingly global nature of science, technology and engineering is a reflection of the implementation of the globally integrated enterprise.  Customers trust wintergreen research to work alongside them to ensure the success of the participation in a particular market segment.

WinterGreen Research supports various market segment programs; provides trusted technical services to the marketing departments.  It carries out accurate market share and forecast analysis services for a range of commercial and government customers globally.  These are all vital market research support solutions requiring trust and integrity.

Companies Profiled
Market Leaders
  • General Electric
  • IBM
Market Participants
  • Alphabet / Google
  • GlaxoSmithKline (GSK)
  • Merck
  • Prognos
  • Quest Diagnostics
  • Safeguard Scientifics
  • Zebra

Report Methodology

This is the 720th report in a series of market research reports that provide forecasts in communications, telecommunications, the internet, computer, software, and telephone equipment. The project leaders take direct responsibility for writing and preparing each report. They have significant experience preparing industry studies. Forecasts are based on primary research and proprietary databases. Forecasts reflect analysis of the market trends in the segment and related segments. Unit and dollar shipments are analyzed through consideration of dollar volume of each market participation in the segment. Market share analysis includes conversations with key customers of products, industry segment leaders, marketing directors, distributors, leading market participants, and companies seeking to develop measurable market share. Over 200 in-depth interviews are conducted for each report with a broad range of key participants and opinion leaders in the market segment.

About the Company

WinterGreen Research, founded in 1985, provides strategic market assessments in telecommunications, communications equipment, health care, and advanced computer technology. Industry reports focus on opportunities that will expand existing markets or develop major new markets. The reports assess new product and service positioning strategies, new and evolving technologies, and technological impact on products, services, and markets. Market shares are provided. Leading market participants are profiled, and their marketing strategies, acquisitions, and strategic alliances are discussed. The principals of WinterGreen Research have been involved in analysis and forecasting of international business opportunities in telecommunications and advanced computer technology markets for over 30 years.

About the Principal Authors

Ellen T. Curtiss, Technical Director, co-founder of WinterGreen Research, conducts strategic and market assessments in technology-based industries. Previously she was a member of the staff of Arthur D. Little, Inc., for 23 years, most recently as Vice President of Arthur D. Little Decision Resources, specializing in strategic planning and market development services. She is a graduate of Boston University and the Program for Management Development at Harvard Graduate School of Business Administration. She is the author of recent studies on worldwide telecommunications markets and the Top Ten Telecommunications market analysis and forecasts.

Susan Eustis, President, co-founder of WinterGreen Research, has done research in communications and computer markets and applications. She holds several patents in microcomputing and parallel processing. She is the author of recent studies of the Service Oriented Architecture (SOA) marketing strategies, Internet software, a study of Push to Talk Equipment, Worldwide Telecommunications Equipment, Top Ten Telecommunications, Digital Loop Carrier, Web Hosting, Business Process Management, Servers, Blades, the Mainframe as a Green Machine, and Application Server markets. Ms. Eustis is a graduate of Barnard College.

$4200 - Single Copy or $8400 - Web Posting | Report # SH272024732 | 124 Pages | 50 Tables and Figures | 2017


Qty
Authorize.net